FAST FACTS
FOUNDER(S):
Dr. J. Joseph Kim
Dr. David Weiner
INNOVATION(S):
Biotechnology/Pharmaceuticals
Cancer Therapies/Tests
Cancer Therapies/Tests
Vaccines
EMPLOYEES:
27
HEADQUARTERS:
Philadelphia, PA
FOUNDED:
2000
REVENUE:
$2.1 million FY08 (Invovio)
TSC MEMBER INSTITUTION(S):
University of Pennsylvania
FUNDING AGENCY(S):
National Institutes of Health
STATUS:
Acquired
ACQUIRING COMPANY:
Inovio Biomedical Corporation
|
VGX PHARMACEUTICALS
ABOUT THE COMPANY:
VGX Pharmaceuticals was formed in 2000 to focus on the discovery and development of novel vaccines and therapies for infectious diseases, including HIV, and cancer. In June 2009, the company completed a merger with Inovio Biomedical Corporation. Inovio focuses on the discovery, development, and delivery of a new generation of vaccines — DNA vaccines — to prevent or treat cancers and chronic infectious diseases.
UNIVERSITY-BASED RESEARCH CONNECTION:
VGX was founded based on several novel DNA vaccine technologies developed in the laboratory of Dr. David B. Weiner, Professor of Pathology and Laboratory Medicine, at the University of Pennsylvania. Professor Weiner is a pioneer in the field of DNA vaccines and a VGX co-founder. Dr. Weiner continues to serve as Chairman of the Inovio Scientific Advisory Board.
ROLE OF FEDERAL RESEARCH FUNDING:
The basic research at the University of Pennsylvania that led to the development of this technology was supported by research grants from the National Institutes of Health.
 Read The Full Report Here
|
Printer-Friendly Version
INOVIO BIOMEDICAL CORPORATION